Literature DB >> 12352011

Sequestration of aggregated low-density lipoproteins by macrophages.

Howard S Kruth1.   

Abstract

PURPOSE OF REVIEW: Evidence suggests that much of the LDL in atherosclerotic plaques is aggregated. Aggregation of LDL could be an important factor that determines how this lipoprotein is metabolized by plaque macrophages and the fate of aggregated LDL cholesterol within plaques. This review discusses a novel endocytic pathway by which macrophages process aggregated LDL. RECENT
FINDINGS: Recently, it has been shown that aggregated LDL can be sequestered in macrophage surface-connected compartments and plasma membrane invaginations by a process termed patocytosis. In contrast to rapid degradation of LDL and aggregated LDL taken up by macrophages through pinocytosis and phagocytosis, respectively, aggregated LDL sequestered in macrophages undergoes only limited degradation. Macrophages can disaggregate and release sequestered aggregated LDL by activating plasminogen to plasmin. Plasmin degrades LDL apolipoprotein B sufficiently to disaggregate the aggregated LDL, releasing it from the macrophage surface-connected compartments. In contrast, activating macrophages with phorbol-myristate-acetate stimulates degradation of aggregated LDL and inhibits plasminogen-mediated release of the aggregated lipoprotein from macrophage surface-connected compartments.
SUMMARY: Macrophage sequestration of aggregated LDL is a unique endocytic pathway relevant not only to the processing of aggregated LDL in atherosclerotic plaques but also for the processing of other materials, such as hydrophobic particles that trigger this endocytic pathway. Macrophage sequestration of aggregated LDL can result in different fates for the aggregated LDL, depending on the state of macrophage activation and the functioning of the plasminogen-based fibrinolytic system. Patocytosis of aggregated LDL should be considered in addition to phagocytosis as a possible uptake pathway in studies of macrophage processing of aggregated LDL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352011     DOI: 10.1097/00041433-200210000-00003

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  28 in total

1.  An integrated approach for the mechanisms responsible for atherosclerotic plaque regression.

Authors:  Andrew A Francis; Grant N Pierce
Journal:  Exp Clin Cardiol       Date:  2011

2.  Macrophages create an acidic extracellular hydrolytic compartment to digest aggregated lipoproteins.

Authors:  Abigail S Haka; Inna Grosheva; Ethan Chiang; Adina R Buxbaum; Barbara A Baird; Lynda M Pierini; Frederick R Maxfield
Journal:  Mol Biol Cell       Date:  2009-10-07       Impact factor: 4.138

3.  Eicosapentaenoic acid and docosahexaenoic acid regulate modified LDL uptake and macropinocytosis in human macrophages.

Authors:  James E McLaren; Daryn R Michael; Irina A Guschina; John L Harwood; Dipak P Ramji
Journal:  Lipids       Date:  2011-08-07       Impact factor: 1.880

4.  Internalization of SiO₂ nanoparticles by alveolar macrophages and lung epithelial cells and its modulation by the lung surfactant substitute Curosurf.

Authors:  Sandra Vranic; Ignacio Garcia-Verdugo; Cécile Darnis; Jean-Michel Sallenave; Nicole Boggetto; Francelyne Marano; Sonja Boland; Armelle Baeza-Squiban
Journal:  Environ Sci Pollut Res Int       Date:  2013-01-05       Impact factor: 4.223

Review 5.  Immune effector mechanisms implicated in atherosclerosis: from mice to humans.

Authors:  Peter Libby; Andrew H Lichtman; Göran K Hansson
Journal:  Immunity       Date:  2013-06-27       Impact factor: 31.745

6.  Lysosomes, cholesterol and atherosclerosis.

Authors:  W Gray Jerome
Journal:  Clin Lipidol       Date:  2010-12-01

Review 7.  Emerging roles of calpain proteolytic systems in macrophage cholesterol handling.

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Cell Mol Life Sci       Date:  2017-04-21       Impact factor: 9.261

8.  Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice.

Authors:  Kathryn J Moore; Vidya V Kunjathoor; Stephanie L Koehn; Jennifer J Manning; Anita A Tseng; Jessica M Silver; Mary McKee; Mason W Freeman
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 9.  HIV-1 assembly in macrophages.

Authors:  Philippe Benaroch; Elisabeth Billard; Raphaël Gaudin; Michael Schindler; Mabel Jouve
Journal:  Retrovirology       Date:  2010-04-07       Impact factor: 4.602

10.  Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice.

Authors:  Jennifer J Manning-Tobin; Kathryn J Moore; Tracie A Seimon; Susan A Bell; Maia Sharuk; Jacqueline I Alvarez-Leite; Menno P J de Winther; Ira Tabas; Mason W Freeman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-10-23       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.